Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2023 September 21, 2023 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis September 15, 2023 argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis August 30, 2023 argenx to Present at Upcoming Investor Conferences July 27, 2023 argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update July 24, 2023 argenx announces closing of global offering July 20, 2023 argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023 July 19, 2023 argenx announces full exercise of underwriters’ option to purchase additional ADSs July 18, 2023 argenx raises $1.1 billion in gross proceeds in a global offering July 17, 2023 argenx announces launch of proposed global offering July 17, 2023 argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy June 30, 2023 argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China June 20, 2023 argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
